S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Exelixis Announces Positive Top-Line Results for Phase 3 Pivotal Trial of Cobimetinib in Combination With Vemurafenib in Patients With BRAF V600 Mutation-Positive Advanced Melanoma|
|Exelixis Announces Positive Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma|
|Exelixis Announces Cobimetinib Phase 3 coBRIM Results to Be Presented at ESMO 2014 Congress|
|Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer|
|Exelixis to Release Second Quarter 2014 Financial Results on Thursday, July 31, 2014|
|Exelixis Announces Second Quarter 2014 Financial Results|
|Exelixis to Present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 9|
|Atlas Air Worldwide Appoints Michael T. Steen President and Chief Executive Officer, Titan Aviation Holdings|
|Genentech’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf® (Vemurafenib), Helped People with Advanced Melanoma Live Significantly Longer Without Their Disease Worsening (2014/7/14)|
|Frances K. Heller Rejoins Zafgen Board of Directors|
Click above to view more mutual fund data and stats for exel - Exelixis Inc.